

2 Figure S1. Basic information of the 140 PCNSL patients

The key demographic and clinical characteristics of PCNSL patients are summarized in the upper half of the figure, while the proportions of patients with these characteristics are presented in the lower half. Related to Figure 1.



7 Figure S2. PCNSL mutational landscape and variation signature

- A: Variant classification, type, and single-nucleotide variation class for PCNSL patients (n =
 140).
- 10 B: Oncogene pathways in 140 PCNSL patients.
- 11 C: Arm-level copy number alterations in 140 PCNSL patients.
- 12 D: Contribution of mutational signatures in 140 PCNSL patients.
- 13 E: The most significant contributions to the PCNSL genome.
- 14 Related to Figure 1.



16 Figure S3. Genetic variation events and tumor mutational burden (TMB) in the 140

17 PCNSL samples

- 18 A: Genetic variation events in 140 PCNSL samples and the TMB of PCNSL, ranking 2nd in
- 19 the TCGA database.
- 20 B: Genetic variation events in the discovery cohort of PCNSL patients (n = 58) and the TMB
- of PCNSL patients, ranking 5th in the TCGA database.
- 22 C: Genetic variation events in the validation cohort of PCNSL patients (n = 82) and the TMB
- of PCNSL patients, ranking 1st in the TCGA database.
- D: The mutually exclusive or co-occurrence relationships of these genes.
- 25 Related to Figure 1.









- Figure S4. Kaplan–Meier estimates of overall survival associated with candidate cancer genes with mutation frequencies exceeding 10% and the NOTCH1, NOTCH2, and EZH2 genes.
- 33 Related to Figure 1.



35 Figure S5. Mutation Profiles and Signatures of the Discovery and Validation Cohorts

A: Variant classification, type, and single-nucleotide variation (SNV) class in the discovery
 cohort of PCNSL patients (n = 58).

B: Variant classification, type, and single-nucleotide variation (SNV) class in the validation
 cohort of PCNSL patients (n = 82).

- C: Number and frequency of recurrent mutations, along with a gene–sample matrix of
 recurrently mutated genes, ranked by mutation frequency in the discovery cohort of PCNSL
 patients (n = 58).
- D: Number and frequency of recurrent mutations, along with a gene–sample matrix of recurrently mutated genes, ranked by mutation frequency in the validation cohort of PCNSL patients (n = 82).
- 46 E: GISTIC2.0 results of significant recurrent focal amplifications (red) and deletions (blue).
- Genes affected by each focal event are annotated in the discovery cohort (n = 58). X-axis:
 plot of chromosomes; Y-axis: G score.
- 49 F: GISTIC2.0 results of significant recurrent focal amplifications (red) and deletions (blue).
- 50 Genes affected by each focal event are annotated in the validation cohort (n = 82). X-axis: 51 plot of chromosomes; Y-axis: G score.
- 52 G: The most significant contributions to the PCNSL genome in the discovery cohort (n = 58).
- 53 H: The most significant contributions to the PCNSL genome in the validation cohort (n = 82).
- 54 Related to Figure 2.





56 Figure S6. The prognostic value of published molecular subtypes for progression-

57 free survival (PFS) and overall survival (OS) in our Chinese PCNSL cohort

- A: Prognostic value of the DLBCL COO molecular subtype (GCB, non-GCB) for OS and
- 59 PFS in our Chinese PCNSL cohort
- B: The prognostic value of DLBCL LymphPlex molecular subtypes (BN2, MCD, EZB, N1,
- TP53, and others) for OS and PFS in our Chinese PCNSL cohort
- 62 C: The prognostic value of M.A. Shipp's team's DLBCL molecular subtypes (C0, C1, C2, C3,
- 63 C4, and C5) for OS and PFS in our Chinese PCNSL cohort
- D: The prognostic value of L.M. Staudt's team's DLBCL molecular subtypes (BN2, EZB,
- 65 MCD, N1, and others) for OS and PFS in our Chinese PCNSL cohort
- E: The prognostic value of L.M. Staudt's DLBCL molecular subtypes (A53, BN2, EZB, MCD,
- 67 N1, ST2, and others) for OS and PFS in our Chinese PCNSL cohort.
- 68 F: Prognostic value of A. Alentorn team's PCNSL molecular subtypes (CS1, CS2, CS3, and
- 69 CS4) for OS and PFS in our Chinese PCNSL cohort
- 70 Related to Figure 3.



71

Figure S7. The prognostic value of the double-hit gene expression signature subtypes for progression-free survival (PFS) and overall survival (OS) in our Chinese

74 PCNSL cohort

A: The prognostic value of double-hit gene expression signature subtypes (double or triple

- ⁷⁶ hit vs. others) for OS and PFS in our Chinese PCNSL discovery cohort (n = 58)
- B: The prognostic value of double-hit gene expression signature subtypes (double or triple
- hit vs. others) for OS and PFS in our Chinese PCNSL validation cohort (n = 82)
- 79 C: The prognostic value of double-hit gene expression signature subtypes (double or triple
- 80 hit vs. others) for OS and PFS in our Chinese PCNSL cohort (n = 140).

81 Related to Figure 3.



83 Figure S8. Schematic of the typing strategies used to identify PCNSL molecular 84 subtypes

- A: CoxNet survival analyses and least absolute shrinkage and selection operator (LASSO)
- regressions were employed to determine the importance score of each feature in the model,
- all of which were then ranked. This process was repeated 500 times, and all potential
 features were recorded. This is a demonstration of the aforementioned process.
- B: Kaplan–Meier (K–M) analyses of the 6 identified features were conducted.
- 90 C: Venn diagram illustrating how these 6 features were randomly combined to form three 91 types.
- 92 D: Seven candidate molecular subtype combinations were identified in the discovery cohort.
- 93 E: Seven candidate molecular subtype combinations were validated in the validation cohort.
- 94 Related to Figure 4.



- 96 Figure S9. Mutation diagrams (Lollipop Figures) for the EP300, IRF4, BTG1, and
- 97 MYD88 genes
- 98 For each gene, all nonsynonymous mutations within the functional domains of the
- 99 respective protein were visualized via maftools.
- 100 Related to Figure 4.



<u>90</u>

0

0

102 Figure S10. Kaplan–Meier analyses of the EP300, IRF4, BTG1, and MYD88 genes and

- 103 molecular subtypes
- 104 A: Prognostic value of mutations in the EP300, IRF4, BTG1, and MYD88 genes for OS.
- 105 B: Prognostic value of mutations in the EP300, IRF4, BTG1, and MYD88 genes for
- 106 progression-free survival (PFS).
- 107 C: Kaplan–Meier estimates of overall survival (OS) and progression-free survival (PFS)
- among 140 PCNSL patients with each molecular subtype.
- 109 Related to Figure 4.



111 Figure S11. Kaplan–Meier estimates of the impact of BTK inhibitor use on prognosis

- 112 A: The prognostic value of BTK inhibitor use for overall survival (OS) in all 140 PCNSL
- 113 patients and patients with each molecular subtype.
- B: Prognostic value of BTK inhibitor use for progression-free survival (PFS) in all 140
- 115 PCNSL patients and patients with each molecular subtype.
- 116 Related to Figure 4.



118 Figure S12. Mutation profiles and signatures across the three MSs

- A. Variant classification, type, and single-nucleotide variation (SNV) class across the E3,
 BMI, and UC subtypes.
- 121 B. GISTIC2.0 results of significant recurrent focal amplifications (red) and deletions (blue).
- 122 Genes affected by each focal event are annotated. X-axis: plot of chromosomes; Y-axis: G 123 score.
- 124 C. Contributions of mutational signatures across the E3, BMI, and UC subtypes.
- D. The most significant contributions to the PCNSL genome across the E3, BMI, and UC subtypes.
- 127 Related to Figure 6.



Figure S13. Hematoxylin–eosin staining and immunohistochemistry (A) for CD2, CD5, CD10, CD19, CD20, CD79a, Ki-67, BCL2, BCL6, MUM1, C-Myc, and p53, and oncogene pathways (B) in samples from different PCNSL subtypes

132 Related to Figure 6.



134 Figure S14. Mutational profiles of deep brain and shallow brain tumors in PCNSL

135 A: Difference in tumor sites in the discovery versus validation cohorts.

136 B: Venn diagram of unique and shared mutations in deep brain and shallow brain tumors.

137 C: The number and frequency of recurrent mutations, along with a gene-sample matrix of

138 recurrently mutated genes in PCNSL patients between deep brain and shallow brain tumors,

are presented. The relative abundance across the molecular subtypes is displayed on theright.

141 D: Arm-level copy number alterations between deep brain and shallow brain tumors are 142 displayed. The frequencies of amplifications and deletions were compared.

E: The levels of mutant-allele tumor heterogeneity (MATH) were compared between deep brain and shallow brain tumors.

F: The tumor mutational burden (TMB) was compared between deep brain and shallow brain tumors.

147 G: The levels of microsatellite instability (MSI) were compared between deep brain and 148 shallow brain tumors.

H: Pathways affected by oncogenes in PCNSL patients between deep brain and shallowbrain tumors.

151 The chi-squared test and one-way ANOVA were used. *P < 0.05, nsP > 0.05

152 Related to Figure 7.